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Abstract
Surgery and antifungals are the reference standard for rhino-
orbito-cerebral mucormycosis (ROCM) treatment. The impact of
local control on survival of 22 consecutive ROCM adults was
studied on day 90: none vs. 75% died, respectively, with or without
local control (p <0.0001). Hence, repeated surgical procedures are
recommended to achieve local control of ROCM.
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Rhino-orbito-cerebral mucormycosis (ROCM) is a life-threat-
ening invasive fungal infection. Early combination of antifungal
therapy and surgical debridement is the reference standard for
treating ROCM [1]. However, the extent of debridement
required to achieve local disease control and its timing to
maximize favourable ROCM outcome have never been deﬁned
[2]. We wondered if radical surgical treatment could improve
local control and, hence, overall survival. From the nationwide
retrospective ‘RetroZygo’ study on mucormycosis patients
from January 2005 to December 2007 [3], we selected those
with ROCM to assess the relationship between the extent of
surgery, local control and overall survival.
From January 2005 to December 2007, the ‘RetroZygo’
study evaluated 101 patients with proven or probable muco-
rmycosis [3]. The most frequent localizations were isolated
pulmonary (n = 28), ROCM (n = 25) or cutaneous (n = 20).
From this cohort, only those with proven or probable ROCM
[4] were selected for the present analysis. Detailed surgical
and radiological reports were obtained for 22/25, with the
latter representing the sample of the present report. For all
patients, the following data were collected: age, sex, medical
history, risk factors for mucormycosis, clinical symptoms,
initial endoscopic ﬁndings, computed tomography and mag-
netic resonance imaging ﬁndings, surgical procedure, antifungal
therapy administered and survival.
Surgical procedures were staged and graded I, II and III,
when the patients underwent isolated diagnostic biopsy (grade
I), debridement of necrotic tissue in the nasal cavity and in the
sinus (grade II), or extended surgical resection (grade III) by
resection of infected tissues, drilling of underlying bone,
exenteration, if necessary, and/or drilling of the skull base.
Local control was deﬁned as (i) the absence of any endoscop-
ically detected necrotic lesion or any local progression of the
infection in the surgical cavity and (ii) the absence of any new
extension on imaging. Overall survival probability was esti-
mated using the Kaplan-Meier method with the log-rank test
for group comparisons. p <0.5 deﬁned signiﬁcance.
Twenty-two ROCM patients (11 male and 11 female;
median age, 59 years (range, 19–83)) were analysed. Seventeen
cases were proven and ﬁve probable. Species were identiﬁed
in 50% (11/22) of the patients and Rhizopus oryzae was found in
10 of them. The main risk factors were diabetes mellitus
(n = 14, 64%, ﬁve of type I) or haematological malignancies
(n = 5, 22%). Six (27%) patients had ketoacidosis and two
patients had undergone haematopoietic stem-cell transplanta-
tion. The main presenting symptoms were unilateral facial pain
(n = 19, 86%), periorbital oedema (n = 13, 59%), fever
(n = 11, 50%) and diplopia (n = 9, 41%). Fifteen patients had
multiple cranial nerve palsies with involvement of the third
(n = 7), fourth (n = 7), ﬁfth (n = 10) and/or sixth (n = 8)
cranial nerves. Black necrotic tissue carpeted the turbinates
and the septal mucosa in nine (40%) patients in addition to
palatal perforation in four (18%); four patients had cognitive
disturbances and four chemosis.
Five patients (23%) underwent grade I surgery, seven (32%)
grade II and ten (45%) grade III procedures (Fig. 1). Among the
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ﬁve patients who underwent grade I surgery, four patients had
a limited lesion, which was entirely removed with a large biopsy,
and local control was achieved. One patient received palliative
care because of the severity of his underlying haematological
disease and the extension of the infection. Among 14 patients in
whom local control was obtained, four presented with an
extension to the skull base, two having a cerebral parenchyma
extension. For patients in whom local control was not achieved
(n = 8), 4/8 (50%) were treated with liposomal amphotericin B
10/mg/kg/day, 2/8 (25%) were treated with posaconazole, 1/8
was treated with amphotericin B lipid complex and 1/8 was
treated with amphotericin B deoxycholate. The mean duration
of treatment was 28 days for liposomal amphotericin B and
25 days for posaconazole. For patients in whom local control
was achieved (n = 14), 8/14 (57%) were treated with liposomal
amphotericin B 10 mg/kg/day, with a mean duration of treat-
ment of 23 days, 4/14 (28%) were treated with posaconazole,
with a mean duration of treatment of 55 days, and 2/14 with
amphotericin B deoxycholate (14%).
Repeated surgical procedures were performed on 45% of
patients for persistance of signs of infection on histological
examination of surgical specimens or further endoscopy
ﬁndings. Univariate analysis selected the following factors as
being signiﬁcantly associated with overall mortality: haemato-
logical malignancy (p <0.0001), chemosis (p 0.0003), sixth
cranial nerve palsy (p 0.027) or cognitive disturbances (p
0.017). The overall survival rate was 57% (13/22), with median
follow-up at 40.3 (range, 0.16–54.8) months: 72.2% at
3 months, 61.9% at 1 year and 56.4% at 18 months. The 3-
month survival rate was 78% for patients with diabetes mellitus
while none of those with haematological malignancies survived.
Survival was signiﬁcantly prolonged when local control had
been achieved (Fig. 2). Three-month survival was 100% when
local control was achieved but only 25% without local ROCM
control (p <0.001, Fig. 1). Local control was obtained in 90% of
the patients after radical surgery and 41.6% without it. At
3 months, survival rates were 80%, 19% or 100%, respectively,
for patients who underwent grade I, II or III surgery (p 0.0002).
Within the past decade, only a few retrospective studies
described more than 15 ROCM patients [5–9] but they did not
examine the impact of local control on outcome, as we did.
ROCM survival rates have ranged from 47% to 75% [5–9]. In
our recent study of consecutive patients, the 3-month and 1-
year survival rates were 72.2% and 61.9%, respectively.
ROCM-induced vascular thrombosis results in tissue necro-
sis and subsequent poor diffusion of antifungals to the infection
site. Therefore, debridement of necrotic tissues appears
determinant for ROCM eradication, and obtaining local
control and deﬁnitive cure. Better survival was achieved in
patients who underwent surgery [1,3]. Blitzer et al. reported
that the survival rate rose from 57.5% to 79% when patients
underwent radical surgery [10]. However, our study carries a
bias, as some ROCM patients did not have adequate
debridement because of the large extension of their infection
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FIG. 1. Flow chart diagram of clinical management and local control. °°Controlled cancer, n = 1; controlled respiratory disease, n = 1; no
underlying disease, n = 1.*Extension to critical anatomical sites. **Initial advanced disease. HM: hematological malignancy.
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at initial evaluation and the severity of their co-morbidities.
Therefore the patients that could not tolerate or who were
not eligible for adequate surgery/control were more likely to
die. Nevertheless, former data and our data support that
radical surgical debridement can optimize ROCM cure rates.
Indeed, at month 3, all of our patients survived when local
control had been achieved, thereby emphasizing the major
impact of local ROCM control on survival. Radical resection
can now be achieved with low morbidity under endoscopic
guidance, which allows large resection of sinus walls to the
skull base and the wide exposure of the orbital walls [7].
Furthermore, the operative ﬁeld can later be easily investi-
gated endoscopically under local anaesthesia to look for
necrosis. Notably, we demonstrated that three clinical signs
signiﬁcantly affected survival: chemosis, sixth cranial nerve
palsy and cognitive disturbances. The presence of these signs
should trigger management with emergency surgery combined
with recommended antifungal treatment [11]. Pertinently, an
earlier study found orbital extension to be associated with
poor survival [12]. Moreover, Talmi et al. reported 100%
mortality when intracranial extension became symptomatic
[6]. That observation is in line with our ﬁndings, because
chemosis, sixth cranial nerve palsy and cognitive disturbances
were indeed associated with orbital or intracranial spread.
In conclusion, surgically obtained local ROCM control
dramatically impacts its prognosis. However, one limitation of
this study is that ROCM patients who did not undergo
adequate debridement because of the severity of initial
extension or co-morbidities were more likely to die. A
prospective study to determine the contribution of systematic
second-look surgery for ROCM should be investigated.
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